• Users Online: 18
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2018  |  Volume : 7  |  Issue : 4  |  Page : 148-153

Soluble ST2: A biomarker to monitor heart failure progression and treatment

1 Division of Cardiovascular Medicine, University of California San Diego, San Diego, California, USA
2 Department of Medicine, University of California, San Diego, California, USA
3 Division of Cardiovascular Medicine, Veterans Affairs Medical Center, San Diego, California, USA
4 Department of Cardiology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Correspondence Address:
Dr. Marin Nishimura
9500 Gilman Dr Mc 7411C La Jolla, California 92093-7411
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCPC.JCPC_41_18

Rights and Permissions

Measurement of cardiac biomarkers has become routine for the care of patients with heart failure (HF). While troponin and natriuretic peptides are well-entrenched in the guidelines, soluble ST2 (sST2) is a novel biomarker that has shown consistent performance and is ready for clinical use. Multiple studies support the use of sST2 in both acute and chronic HF for prognostication. We suggest a novel scheme to guide HF management based on ambulatory sST2 levels.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded733    
    Comments [Add]    
    Cited by others 5    

Recommend this journal